An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.

ABSTRACT:

SUBMITTER: Gupta R 

PROVIDER: S-EPMC7717427 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature